ArticleACR open rheumatology2022
Cardiovascular and Venous Thromboembolic Risk With Janus Kinase Inhibitors in Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis of Randomized Trials.
Article in ACR open rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis.Annals of medicine · 2025Pooled it
- Review: progression and heterogeneity of multiple sources of mesenchymal stromal cells for the treatment of rheumatoid arthritis.Stem cell research & therapy · 2025Pooled it
- JAK Inhibitors in Colchicine Resistant FMF Patients: A Case-Based Review.Mediterranean journal of rheumatology · 2026Article
- Venous thromboembolism in bullous pemphigoid: current evidence from an updated systematic review.Dermatology reports · 2025Article
- Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database.Drug safety · 2025Article
- Investigating associations between JAK inhibition and venous thromboembolism by systematic mining of large-scale datasets.Inflammopharmacology · 2025Article
- American society for preventive cardiology 2024 cardiovascular disease prevention: Highlights and key sessions.American journal of preventive cardiology · 2025Review
- Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system.Frontiers in pharmacology · 2025Article
- Choosing Therapies in Ulcerative Colitis.Journal of the Canadian Association of Gastroenterology · 2024Article
- Article
- Novel Imaging Approaches to Cardiac Manifestations of Systemic Inflammatory Diseases: JACC Scientific Statement.Journal of the American College of Cardiology · 2023Review
- Beyond the Surface: Investigating the Relationship Between Autoimmune Blistering Disorders and Venous Thromboembolism.Journal of the American Heart Association · 2023Article
- The Emerging Safety Profile of JAK Inhibitors in Rheumatic Diseases.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience.Journal of clinical medicine · 2023Review
- Evidence for Biologic Drug Modifying Anti-Rheumatoid Drugs and Association with Cardiovascular Disease Risk Mitigation in Inflammatory Arthritis.Rheumatic diseases clinics of North America · 2023Review
- Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs.Clinical, cosmetic and investigational dermatology · 2023Review
- JAK inhibitors and black box warnings: what is the future for JAK inhibitors?Expert review of clinical immunologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveJanus kinase (JAK) inhibition effectively treats immune-mediated inflammatory diseases (IMIDs); however, concern over the risk of major adverse cardiac events (MACE) and venous thromboembolism (VTE) remains. We aimed to evaluate the safety (VTE and MACE outcomes) of JAK inhibitors in the treatment of IMIDs.
methodsA search in PubMed, Embase, and ClinicalTrials.gov databases was conducted for randomized clinical trials (RCTs) of JAK inhibitors across IMIDs. Primary outcomes were VTE and MACE with JAK inhibitors compared with placebo and active comparator arms stratified by follow-up time.
resultsSixty-six RCTs enrolled 38,574 patients with a mean age of 48.8 years and a mean follow-up of 10.5 months. JAK inhibitors had a numerically higher rate of VTE when compared with controls (odds ratio [OR] 1.65; 95% confidence interval [CI]: 0.97-2.79), driven by trials with a follow-up duration of 12 or more months (OR 2.17; 95% CI: 1.16-4.05; P
conclusionJAK inhibitors when compared with active comparator arms increased the risk of VTE, which was dependent on duration of exposure. Future clinical trials with extended follow-up are needed to clarify the safety profiles of JAK inhibitors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.